Mendelian randomization identifies OX40 as a potential mediator of the effects of cigarette smoking in palmoplantar pustulosis

Collaborators, Affiliations

¹ Department of Medical and Molecular Genetics, King's College London, London, UK.
² St John's Institute of Dermatology, King's College London, London, UK.
³ School of Infection and Immunity, University of Glasgow, Glasgow, UK.
⁴ NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
⁵ Department of Dermatology, King's College Hospital, King's College London, London, UK.
⁶ Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle NIHR Biomedical Research Centre and the Department of Dermatology, Royal Victoria Infirmary, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
⁷ Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
⁸ Boehringer Ingelheim Pharmaceuticals, Ridgefield, USA.
⁹ HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, NTNU- Norwegian University of Science and Technology, Trondheim, Norway and Department of Dermatology, Clinic of Orthopedy, Rheumatology; Dermatology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
¹⁰ BC Children's Hospital Research Institute, Vancouver; Department of Medical Genetics and Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada.

Alice Smail et al. Br J Dermatol. 2025.

. 2025 Jul 17:ljaf280.

doi: 10.1093/bjd/ljaf280. Online ahead of print.

¹ Department of Medical and Molecular Genetics, King's College London, London, UK.
² St John's Institute of Dermatology, King's College London, London, UK.
³ School of Infection and Immunity, University of Glasgow, Glasgow, UK.
⁴ NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
⁵ Department of Dermatology, King's College Hospital, King's College London, London, UK.
⁶ Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle NIHR Biomedical Research Centre and the Department of Dermatology, Royal Victoria Infirmary, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
⁷ Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
⁸ Boehringer Ingelheim Pharmaceuticals, Ridgefield, USA.
⁹ HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, NTNU- Norwegian University of Science and Technology, Trondheim, Norway and Department of Dermatology, Clinic of Orthopedy, Rheumatology; Dermatology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
¹⁰ BC Children's Hospital Research Institute, Vancouver; Department of Medical Genetics and Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada.

No abstract available

Save citation to file